The Role of Vimentin in Human Corneal Fibroblast Spreading and Myofibroblast Transformation.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
25 Jun 2024
Historique:
received: 08 06 2024
accepted: 22 06 2024
medline: 12 7 2024
pubmed: 12 7 2024
entrez: 12 7 2024
Statut: epublish

Résumé

Vimentin has been reported to play diverse roles in cell processes such as spreading, migration, cell-matrix adhesion, and fibrotic transformation. Here, we assess how vimentin impacts cell spreading, morphology, and myofibroblast transformation of human corneal fibroblasts. Overall, although knockout (KO) of vimentin did not dramatically impact corneal fibroblast spreading and mechanical activity (traction force), cell elongation in response to PDGF was reduced in vimentin KO cells as compared to controls. Blocking vimentin polymerization using Withaferin had even more pronounced effects on cell spreading and also inhibited cell-induced matrix contraction. Furthermore, although absence of vimentin did not completely block TGFβ-induced myofibroblast transformation, the degree of transformation and amount of αSMA protein expression was reduced. Proteomics showed that vimentin KO cells cultured in TGFβ had a similar pattern of protein expression as controls. One exception included periostin, an ECM protein associated with wound healing and fibrosis in other cell types, which was highly expressed only in Vim KO cells. We also demonstrate for the first time that LRRC15, a protein previously associated with myofibroblast transformation of cancer-associated fibroblasts, is also expressed by corneal myofibroblasts. Interestingly, proteins associated with LRRC15 in other cell types, such as collagen, fibronectin, β1 integrin and α11 integrin, were also upregulated. Overall, our data show that vimentin impacts both corneal fibroblast spreading and myofibroblast transformation. We also identified novel proteins that may regulate corneal myofibroblast transformation in the presence and/or absence of vimentin.

Identifiants

pubmed: 38994947
pii: cells13131094
doi: 10.3390/cells13131094
pii:
doi:

Substances chimiques

Vimentin 0
Transforming Growth Factor beta 0
Withanolides 0
withaferin A L6DO3QW4K5

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIH HHS
ID : P30 EY030413
Pays : United States
Organisme : NIH HHS
ID : R01 EY013322
Pays : United States
Organisme : Research to Prevent Blindness
ID : Challenge Grant

Auteurs

Miguel Miron-Mendoza (M)

Department of Ophthalmology, UT Southwestern Medical Center, Dallas, TX 75390, USA.

Kara Poole (K)

Department of Ophthalmology, UT Southwestern Medical Center, Dallas, TX 75390, USA.

Sophie DiCesare (S)

Department of Ophthalmology, UT Southwestern Medical Center, Dallas, TX 75390, USA.

Emi Nakahara (E)

Department of Ophthalmology, UT Southwestern Medical Center, Dallas, TX 75390, USA.

Meet Paresh Bhatt (MP)

Department of Ophthalmology, UT Southwestern Medical Center, Dallas, TX 75390, USA.

John D Hulleman (JD)

Department of Ophthalmology, UT Southwestern Medical Center, Dallas, TX 75390, USA.

Walter Matthew Petroll (WM)

Department of Ophthalmology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Department of Biomedical Engineering, UT Southwestern Medical Center, Dallas, TX 75390, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH